Medical/Pharmaceuticals
International Health Experts: China's Experience Benefits Global Health Governance
BEIJING, Sept. 28, 2025 /PRNewswire/ -- A news report from Xinhua Finance, "Over the past few years, we have seenChina gradually increase its universal health coverage, boost investment, and place great emphasis on preventive medicine. While advancing its 'Healthy China 2030' initiative,China has...
2025-09-28 20:50
2142
The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development
SINGAPORE, Sept. 26, 2025 /PRNewswire/ -- The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded fromSeptember 24-26, 2025. The conference brought together leading biopharmaceutical companies and rese...
2025-09-27 10:45
4917
Datasea Reports Record Fiscal Year 2025 Revenue of $71.62 Million, Up 199% Year-over-Year
DTSS Achieves Fourth Quarter Net Income Breakeven Driven by Cutting-Edge Acoustics and AI Multimodal Digitalization; Ongoing Commercialization Updates in the Coming Weeks BEIJING, Sept. 26, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based high-tech ente...
2025-09-26 21:30
6302
Concord Medical Reports Financial Results for the First Half of 2025
BEIJING, Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced its unaudited consolidated financial results for t...
2025-09-26 19:30
4068
Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
BEIJING, SHANGHAI and BOSTON, Sept. 25, 2025 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK)today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, repr...
2025-09-26 08:47
2621
Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001
BOSTON, Sept. 25, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation, today announced two landmark achievements for its lead program, BBT001. Last week, Ba...
2025-09-25 22:04
4010
The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer
SAN FRANCISCO, Sept. 25, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the US wholly-owned subsidiary of Beijing Biostar Biopharmaceutical Co., Ltd. ("Biostar," stock code: 2563.HK) which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of ...
2025-09-25 21:37
2849
Flat Medical Establishes Clinical Advisory Board for Pain Interventions, Names Dr. Krishnan Chakravarthy as Chairman
AUSTIN, Texas, Sept. 25, 2025 /PRNewswire/ -- Flat Medical, a leading innovator in medical device solutions, today announced the formation of itsClinical Advisory Board for Chronic Pain Interventions and the appointment of Dr. Krishnan Chakravarthy, MD, PhD, as its inaugural Chairman. This strate...
2025-09-25 21:00
2214
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability
* TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. * The platform has achieved an average mAb titer exceeding 8.0 g/L with over 99% of clonal cell lines maintaining sta...
2025-09-25 19:42
2599
Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials
SEOUL, South Korea and MONTREAL, Sept. 24, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, today announced a strategic partnership with CellCarta, a globally recognized provider of CRO laboratory services for p...
2025-09-24 21:00
3032
GCCL and Frontage Laboratories Announce Strategic Collaboration to Strengthen Global Clinical Trial Capabilities
YONGIN, South Korea, Sept. 24, 2025 /PRNewswire/ -- GCCL (Global Clinical Central Lab), aSouth Korea-based leading provider of clinical trial sample analysis, and Frontage Laboratories, Inc., aUSA based full-service contract research organization (CRO), announced on September 23 that they had sig...
2025-09-24 13:29
2834
Noul Secures FDA Registration for Cervical Cancer Diagnostic Cartridge
* FDA registration fulfills requirements for U.S. market entry * Initial shipments to Europe and Latin America to begin with pre-approved countries YONGIN, South Korea, Sept. 23, 2025 /PRNewswire/ -- Noul Co., Ltd. (CEO:David Lim), a medical AI company specializing in blood and cancer diagnos...
2025-09-23 21:00
2074
HKeyBio Lauched the Most Comprehesive Non-human Primate Autoimmune & Allergic Disease Model Matrix to Redefining Clinical Translation
BOSTON and SUZHOU, China, Sept. 23, 2025 /PRNewswire/ -- HKeyBio, a CRO specializing in preclinical and translational autoimmune-drug development, today announced the launch ofHKEY-NHP-MATRIX2.0, a next-generation platform designed to improve the reliability of translating novel autoimmune and al...
2025-09-23 20:35
2955
Mindray Unveils Project 2030 and Re-writes the Future of Women's Health Ultrasound at ISUOG
CANCUN, Mexico, Sept. 23, 2025 /PRNewswire/ -- On September 15th, at ISUOG 2025 World Congress inCancun, Mexico, Mindray unveiled Project 2030, an initiative to improve global access to ultrasound technology. The project was launched to an international audience of leading specialists, capping a ...
2025-09-23 13:48
1964
GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea
YONGIN, South Korea, Sept. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) inSouth Korea for a Phase 1 clinical tria...
2025-09-23 09:41
2421
Galux Demonstrates De Novo Antibody Design With Structural and Functional Validation Across Eight Targets
* Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody * Findings highlight broad therapeutic applicability across oncology, immune, and metabolic diseases SEOUL, South Korea, Sept. 22, 2025 /PRNewswire...
2025-09-22 21:00
2532
Lunit and Agilent Technologies Announce Collaboration to Enhance Development of Companion Diagnostic Solutions Powered with AI for Precision Medicine
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities SEOUL, South Korea, Sept. 22, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeuti...
2025-09-22 21:00
2857
LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting
BEIJING, Sept. 22, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious ...
2025-09-22 20:00
6392
Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-β Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer
HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independently developed TIGIT/TGF-β bifunctional antibody fusion protein, in combination with ivonescimab ...
2025-09-22 14:51
2525
Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy
- The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). The incidence of vomiting was 6.7% in ASC47 in combinationwith semaglutide group compared to 57.1% in the sem...
2025-09-22 08:10
2576
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
YY Group Enters New Era as YYForce, Expanding AI, Automation and Human-Robot Workforce Strategy; Nasdaq Ticker Changes to "YFOR"
2026-09-01 04:10
8287
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
2026-09-01 11:00
8280
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
8092
